In this study, the clinical characteristics of patients with advanced lung adenocarcinoma with EGFR 19Del, L858R mutation were retrospectively analyzed, and the efficacy of targeted combined with platinum two-drug chemotherapy was compared with that of targeted therapy alone. The gene discussed is EGFR; the disease is lung adenocarcinoma.